Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 7c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eagle Pharmaceuticals (EGRX) PT Raised to $66 at RBC Capital
March 1, 2019 6:44 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $66.00 (from $64.00) while maintaining a Outperform rating following results.
"EGRX reported 4Q this morning that brought few material updates," Stanicky commented. "Notably, the coming weeks/months should bring... More
